Shenzhen Chipscreen Biosciences Co Ltd
SSE:688321
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
13.01
24.93
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Shenzhen Chipscreen Biosciences Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Long-Term Debt
Shenzhen Chipscreen Biosciences Co Ltd
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shenzhen Chipscreen Biosciences Co Ltd
SSE:688321
|
Long-Term Debt
¥1.1B
|
CAGR 3-Years
350%
|
CAGR 5-Years
92%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Long-Term Debt
¥104.5m
|
CAGR 3-Years
9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Long-Term Debt
¥158.1m
|
CAGR 3-Years
11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-6%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Long-Term Debt
¥58.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
19%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Long-Term Debt
¥195.6m
|
CAGR 3-Years
43%
|
CAGR 5-Years
118%
|
CAGR 10-Years
42%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Long-Term Debt
¥192.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Shenzhen Chipscreen Biosciences Co Ltd
Glance View
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of small molecule drugs. The company is headquartered in Shenzhen, Guangdong and currently employs 909 full-time employees. The company went IPO on 2019-08-12. The firm focuses on the research and development of original innovative drugs in five therapeutic areas, including malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases and anti-virus. The firm's main products include Chidamide, Siglitazone, Cioroni and CS12192. The firm mainly conducts its businesses in the domestic market.
See Also
What is Shenzhen Chipscreen Biosciences Co Ltd's Long-Term Debt?
Long-Term Debt
1.1B
CNY
Based on the financial report for Sep 30, 2024, Shenzhen Chipscreen Biosciences Co Ltd's Long-Term Debt amounts to 1.1B CNY.
What is Shenzhen Chipscreen Biosciences Co Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
92%
Over the last year, the Long-Term Debt growth was 22%. The average annual Long-Term Debt growth rates for Shenzhen Chipscreen Biosciences Co Ltd have been 350% over the past three years , 92% over the past five years .
You don't have any saved screeners yet
